



Review article

Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients



Merel M. Tielemans^{a,1}, Gerben A.J. van Boekel^{b,1,2}, Teun van Gelder^c, Eric T. Tjwa^a, Luuk B. Hilbrands^{b,*}

^a Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands

^b Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Nephrology, Nijmegen, the Netherlands

^c Department of Internal Medicine and Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

ARTICLE INFO

Keywords:

Maintenance therapy
Immunosuppressive drugs
Kidney transplantation
Pharmacokinetics
Gastrointestinal tract
Adverse events

ABSTRACT

Gastrointestinal (GI) discomfort is common after renal transplantation and can be caused by the use of various immunosuppressive drugs. GI symptoms affect the quality of life, lead to an impaired graft survival and an increased mortality. Moreover, diseases and disturbances of the GI tract also affect the pharmacokinetics of immunosuppressive drugs. This review addresses the interaction between immunosuppressive agents and GI disorders.

The GI tract is involved in the metabolism of several immunosuppressive drugs. Calcineurin inhibitors, mTor inhibitors, and corticosteroids are subjected to metabolism by the intestinal cytochrome P450 (CYP3A) and by the drug efflux pump ABCB1. Mycophenolate is partly metabolized in the stomach and intestine and undergoes enterohepatic recirculation. Gastrointestinal disturbances can lead to a modified exposure to immunosuppressive drugs. In the first and second part of this review, we focus on the role of the GI tract in the pharmacokinetics of the immunosuppressive drugs and how to adjust immunosuppressive therapy in patients with vomiting, need for tube feeding, delayed gastric emptying, intestinal resection, and diarrhea.

In the third part, we review the GI adverse effects of the various immunosuppressive drugs, with special attention for diarrhea and dyspepsia.

Finally, we discuss the effects of drugs used for relief of GI complaints on the exposure to immunosuppressive agents.

© 2018 Elsevier Inc. All rights reserved.

Contents

1.	Introduction	56
2.	Normal intestinal absorption and metabolism of immunosuppressive drugs	56
2.1.	Calcineurin inhibitors, mTor inhibitors and corticosteroids	56
2.2.	Antiproliferative agents.	56
3.	Effects of ageing on metabolism of immunosuppressive medication	57
4.	Consequence of gastrointestinal abnormalities and diseases on the exposure to immunosuppressive drugs	57
4.1.	Vomiting	57
4.2.	Tube feeding	57
4.3.	Gastroparesis	58
4.4.	Intestinal resection	58
4.5.	Bariatric surgery	58
4.6.	Diarrhea	58
5.	Gastrointestinal side effects of immunosuppressive drugs.	58
5.1.	Tacrolimus	58
5.2.	Cyclosporine.	58

* Corresponding author at: Department of Nephrology (internal postal code 464), Radboud university medical center, PO Box 9101, 6500 HB Nijmegen, the Netherlands.
E-mail address: luuk.hilbrands@radboudumc.nl (L.B. Hilbrands).

¹ Both authors contributed equally

² Current affiliation: Department of Internal Medicine, Diaconessen hospital, Utrecht, the Netherlands

5.3.	mTOR inhibitors	59
5.4.	Mycophenolate	59
5.5.	Azathioprine	59
5.6.	Corticosteroids	59
5.7.	Belatacept	60
6.	Interaction between drugs targeting the gastrointestinal tract and immunosuppressive drugs.	60
6.1.	Prokinetic agents	60
6.2.	Antacids	60
6.3.	Proton pump inhibitors	60
6.4.	H2 antagonists	60
6.5.	Helicobacter pylori eradication regimens	60
6.6.	Loperamide and laxatives	60
7.	Conclusion	60
	Funding	60
	Declaration of interest	61
	References.	61

1. Introduction

The current practice in maintenance immunosuppressive therapy for renal allograft recipients is to make use of a combination of various drugs that interfere with different steps in the immune response. These drugs are generally classified according to their mechanism of action: calcineurin inhibitors (CNI) which consist of cyclosporine A (CsA) and tacrolimus, mammalian target of rapamycin (mTOR) inhibitors to which sirolimus and everolimus belong, antiproliferative drugs, which include mycophenolate and azathioprine (AZA), and corticosteroids (CS).

Several factors, including diet, co-administration of drugs or herbs, and genetic features affect the blood concentration of these immunosuppressive drugs. It is not always recognized that disorders of the gastrointestinal (GI) tract like vomiting or diarrhea can also contribute to a modified exposure to immunosuppressive drugs. Moreover, some drugs that are used to treat these conditions can interact with the immunosuppressive agents.

GI adverse events, occurring in >80% of patients after renal transplantation, can also be a consequence of the use of immunosuppressive drugs [1]. The most commonly reported GI complaints are dyspepsia, abdominal pain, diarrhea, and constipation. GI complications, and particularly diarrhea, are associated with poor graft outcome and patient survival [2]. In addition, GI complaints can have detrimental effects on quality of life, which might result in reduced compliance with the immunosuppressive regimen. This in turn is a risk factor for graft failure [3].

Knowledge on the effects of GI tract disorders on the pharmacokinetics of immunosuppressive drugs is essential for prescribing the optimal immunosuppressive regimen. Therefore, we will firstly discuss the role of the GI tract in the pharmacokinetics of the major immunosuppressive drugs. Secondly, we will address the consequences of GI disorders on the pharmacokinetics of immunosuppressive drugs and provide some practical recommendations how to adjust the treatment regimen in these circumstances. Thirdly, we will summarize the GI adverse effects of immunosuppressive drugs, and finally the effects of medical treatment of GI complaints on the pharmacokinetics of immunosuppressive agents will be highlighted.

2. Normal intestinal absorption and metabolism of immunosuppressive drugs

2.1. Calcineurin inhibitors, mTor inhibitors and corticosteroids

CsA and tacrolimus are available in different formulations with their own pharmacokinetic characteristics. There are two formulations of CsA available in capsules: oil based and micro-emulsion. In this review, we

will only address the micro-emulsion formulation of CsA which is predominantly prescribed because of a better and more predictable oral bioavailability [4]. Three formulations of tacrolimus are yet available: regular, prolonged-release and prolonged-release with innovative drug delivery technology (LifeCyclePharma, LCP). With prolonged-release formulations, tacrolimus is released further along the GI tract and these formulations can be taken once daily. LCP-tacrolimus is a prolonged-release formulation with a higher bioavailability due to its specific drug delivery technology [5].

CNIs, mTOR inhibitors and CS are all metabolized primarily by CYP3A4 and CYP3A5. They are also substrates of the drug efflux pump ABCB1, previously known as P-glycoprotein. CYP3A enzymes and ABCB1 form a cooperative barrier against absorption of xenobiotics. The absorption of drugs by enterocytes and subsequent excretion by ABCB1 can be repeated multiple times along the GI tract. The consequent repeated exposure to CYP3A enzymes increases the probability of the drug being metabolized. ABCB1 keeps intracellular drug concentrations within the linear range of the metabolizing capacity of the CYP3A enzymes [6]. The CYP3A isoenzymes metabolize immunosuppressive drugs by hydroxylation and demethylation. Several studies showed that differences in expression of CYP3A4, CYP3A5 and ABCB1 cause patient-to-patient variability in the absorption and intestinal metabolism of drugs [7,8].

CYP3A4 is the predominant CYP3A isoform in the GI tract, with an increase in the expression from stomach to the jejunum and then a decrease in the ileum [9]. The intestinal expression of CYP3A5 seems to be only relevant in carriers of the CYP3A5*1 allele (expressers), and is especially present in stomach and ileum [7,8]. Expressers have a faster intestinal tacrolimus metabolism than non-expressers. The ABCB1 expression is equally distributed in stomach, jejunum and ileum [9]. A number of characteristics concerning intestinal absorption and metabolism of the different immunosuppressive drugs are summarized in Table 1.

2.2. Antiproliferative agents

Currently, two mycophenolate compounds are available: mycophenolate mofetil (MMF) and enteric coated mycophenolate sodium (EC-MPS). In both cases, mycophenolic acid (MPA) is the active drug moiety. After oral administration, MMF and EC-MPS are extensively hydrolyzed to MPA by esterases in the stomach, small intestine, blood, liver and other tissues. Uridine diphosphate glucuronosyltransferases metabolize MPA in the liver, and to a lesser extent in the GI tract and the kidneys. The major metabolite is the pharmacologically inactive 7-O-MPA-glucuronide (MPAG), which is excreted into bile. Biliary excretion of MPAG is followed by intestinal deconjugation through colonic bacteria after which MPA can be reabsorbed. This results in an

Table 1

Time to reach the maximum concentration, oral bioavailability, interference of food intake and polymorphism of metabolizing enzymes of the different immunosuppressive agents.

		T _{max}	Oral bioavailability	Interference of food intake	Polymorphisms affecting metabolism
Tacrolimus	Regular	1–2 h [106]	20–25% [107]	Fatty meal decreases exposure with 33% [108]	CYP3A4*22 ^[109]
	Prolonged-release	2–3 h [112,113]	20–25% ^a [113]	Food decreases exposure with 25% [112]	CYP3A5 [110]
	LCP	6 h [114]	26–33% [114]	Food decreases exposure with 55% [115]	POR*28 ^b [111]
Sirolimus		1.5–2 h [116]	15% [117]	Fatty meal increases exposure with 35% [118]	CYP3A5 [119]
Everolimus		1–2 h [120]	16% [120]	Fatty meal decreases exposure with 16% [121]	CYP3A4*22 ^[122]
Cyclosporine (microemulsion)		1.5–2 h [123]	40% [124]	Fatty meal decreases exposure with 15% [124]	CYP3A4*22 ^[122]
Steroids		1–3 h [125]	90% [125]	No effect on exposure [125]	None
Mycophenolate mofetil		1–2 h [29]	81–87% [10,29]	No effect on exposure [29]	None
Enteric-coated mycophenolate sodium		1.5–2.75 h [29]	72% [28]	No effect on exposure [29]	None
Azathioprine		1–2 h [126]	47% [126]	Unknown	None

LCP: prolonged-release with LifeCyclePharma delivery technology.

^a Investigated with the regular formulation.^b Only in CYP3A5 expressers.

important enterohepatic recirculation of MPA/MPAG, which is reflected in a second peak in the MPA concentration-time curve 6–12 h after the ingestion of MMF and accounts for 10%–60% of the total MPA exposure [10]. CsA inhibits the biliary excretion of MPAG and therefore also the enterohepatic recirculation [11–13]. Consequently, patients treated with CsA usually require a higher dose of MMF than patients not treated with CsA [14].

After absorption, approximately 90% of the prodrug AZA undergoes conversion to 6-mercaptopurine (6-MP) by sulphhydryl-containing compounds that are present in every mammalian cell [15]. In a study with healthy volunteers, AZA was administered at different locations in the GI tract [16]. The exposure to 6-MP was highest when AZA was administered in the jejunum and lowest when AZA was delivered in the cecum, indicating that the small bowel is important in absorption of AZA.

3. Effects of ageing on metabolism of immunosuppressive medication

Ageing is associated with changes in pharmacodynamics and pharmacokinetics. Elderly renal transplant patients have a reduced risk of acute rejection but an increased risk to die from infectious complications. The amount of body fat increases, which results in an increased distribution volume for lipophilic drugs, such as tacrolimus and CsA. Elderly renal transplant patients are at increased risk for drug-drug interactions and adverse effects, including nephrotoxicity.

A prospective study that assessed tacrolimus through levels in several age groups, found that advanced age and CYP 3A5*1 were associated with higher dose and weight adjusted through levels, indicating an age related decline in clearance [17]. A similar effect of age on through levels was observed for CsA. In the nEverOld Trial, pharmacokinetics of MPA was not different between younger and older renal transplant patients [18].

4. Consequence of gastrointestinal abnormalities and diseases on the exposure to immunosuppressive drugs

4.1. Vomiting

In general, vomiting reduces the absorption of immunosuppressive drugs, particularly if drugs have not yet passed the stomach and duodenum. If the pills appear to be complete in the vomit or patients throw up within 0.5 h after ingestion, it is typically recommended to take the full dose again. When absorption of immunosuppressive drugs is insufficient due to ongoing vomiting, it is common practice to administer higher doses of CS intravenously to avoid underimmunosuppression. If complaints persist for >24 h, the CNI is usually administered intravenously. Based on the bioavailability of tacrolimus, a dose conversion ratio of 4:1 (oral:intravenous) is recommended. The aim with

continuous intravenous infusion is to attain blood concentrations that are 1.4 times higher than target trough levels applied for regular oral use [19].

CsA can also be administered intravenously with a recommended dose conversion ratio of 3:1 [20]. It has been estimated that the target blood concentration of CsA during continuous intravenous administration has to be 2.55 times higher than the target trough level with oral administration [19].

GI adverse effects of MMF, like vomiting and diarrhea have still been reported during intravenous infusion [21]. Therefore, this drug is often discontinued if patients suffer from vomiting.

AZA can be given intravenously in a reduced dosage accounting for the bioavailability of about 50%. Sirolimus and everolimus are poorly soluble in water and can therefore only be given orally.

In patients who vomit but otherwise have a normal function of the GI tract, some drugs can also be administered rectally. Rectal administration of powder obtained from the oral tacrolimus capsules results in systemic exposure and might represent an alternative for oral administration [22]. Additional research should establish the optimal dose and dosing frequency for rectal administration. In contrast, CsA cannot be administered rectally since it leads to negligible systemic exposure [23]. Finally, CS may also be rectally administered since hydrocortisone as rectal suppository resulted in adequate systemic exposure [24].

4.2. Tube feeding

Direct enteral feeding through a nasogastric tube is required for patients who cannot eat normally, but have an intact GI tract like ventilated patients. Potential issues in these patients are the possibility to crush tablets and the bioequivalence of available alternatives such as sublingual and rectal administration (see above).

A tacrolimus suspension is available for administration via a nasogastric feeding tube. However, the bioavailability of this suspension is reduced due to incomplete solubility or absorption [25]. An alternative might be to administer the drug sublingually, but data on the absorption after sublingual administration are contradictory [22,26].

CsA solution can be administered by a nasogastric feeding tube in the same dose as taken in tablets. Adequate trough levels of CsA were obtained using this way of administration [27].

Sirolimus is available as a solution and everolimus as a dispersible tablet. A study with stable renal allograft patients who were converted from the liquid to tablet formulation of sirolimus, demonstrated near bioequivalence for the two formulations [28].

CS are available in a liquid formulation for administration via a feeding tube, the dose being similar to the dose in tablets.

MMF can be given in a suspension formulation via a feeding tube [29]. However, if the tip of the tube is situated in the duodenum this can result in reduced de-esterification of MMF and decreased exposure to MPA. EC-MPS tablets should not be crushed prior to ingestion to

maintain the integrity of their enteric coating. Therefore, they are not suited for administration via a nasogastric tube.

Finally, AZA cannot be given via a nasogastric feeding tube since the tablet cannot be crushed and a liquid formulation is not available.

4.3. Gastroparesis

Gastroparesis is a syndrome characterized by delayed gastric emptying in the absence of mechanical obstruction. Diabetes mellitus and previous surgery are common causes of gastroparesis, but it is idiopathic in a considerable number of cases [30]. The time course of gastric emptying can affect the absorption of several immunosuppressive agents. The bioavailability of CsA is markedly impaired by gastroparesis [31]. Although the rate of tacrolimus absorption, reflected by the time to achieve maximum blood concentration, is delayed by gastroparesis, total absorption and exposure are unaffected [32]. The effect on exposure to other immunosuppressive agents has not been studied.

Tacrolimus has a prokinetic effect on the GI tract via motilin receptors. In contrast, CsA does appear to slow gastric emptying of solids [33]. Tacrolimus is therefore the CNI of choice in patients with gastroparesis [34]. Since mTOR inhibitors also have prokinetic properties, they might be an alternative to tacrolimus [35]. AZA, mycophenolate and CS do not affect gastric emptying [33,35].

4.4. Intestinal resection

Absorption of CNIs, mTOR inhibitors and CS particularly takes place in the upper GI tract (duodenum and proximal jejunum) and the effect on blood concentrations is most pronounced if this part of the tract has been resected [36]. Consequently, the absorption capacity is diminished after intestinal resection, but the pattern of the concentration-time curve of CNI is similar to that in subjects with a normal GI tract [37]. After a jejunioileal bypass, therapeutic blood concentrations can be achieved with an elevated dose of a CNI [38].

There are no data about the effect of intestinal resection on the absorption of mTOR inhibitors.

As discussed previously, mycophenolate undergoes enterohepatic recirculation, which contributes approximately 40% to the area under the concentration time curve [29]. Consequently, ileostomy can severely reduce the blood concentration of MPA [39].

The exposure to oral CS has reported to be normal in patients who underwent intestinal resection, although concomitant hypoalbuminemia seems to reduce the exposure to CS [40]. The effect of intestinal resection on the absorption of AZA is unknown.

In all patients with intestinal resection, more intensive pharmacokinetic monitoring of immunosuppressive drugs is recommended. Before transplantation, pharmacokinetic measurements after a single or multiple test doses can be performed to provide an estimation of an appropriate starting dose after transplantation. An alternative approach might be to use belatacept instead of a CNI since the intravenous dosing schedule (once every 2–4 weeks) warrants adequate exposure.

4.5. Bariatric surgery

A frequently performed bariatric operation is the Roux-en-Y gastric bypass that results in an intended decreased stomach capacity and a bypass of the duodenum and first part of the jejunum. Limited data are available about the absorption of immunosuppressive drugs in patients with a Roux-en-Y gastric bypass. A study in two renal transplant patients after gastric bypass surgery using tacrolimus or MPA demonstrated that the AUC: dose ratio was significantly lower in both patients after bariatric surgery than in controls without gastric bypass [41]. Proposed mechanisms include an increase in stomach pH, decreased gastric mixing capacity, reduced exposure of hydrophobic drugs to bile acids, and a decrease in absorptive area [42]. Sleeve gastrectomy is another effective surgical intervention to lose weight in

obese patients. One pilot cross-over study assessed pharmacokinetics of immunosuppressive medication in patients with a sleeve gastrectomy. This study concluded that no specific drug changes are necessary and standard therapeutic drug monitoring is recommended [43].

4.6. Diarrhea

Diarrhea, defined as >3 loose stools per day, is the result of inflammation, infection or malabsorption amongst other causes. Diarrhea leads to an enhanced exposure to tacrolimus which can be explained by two mechanisms. Firstly, the oral bioavailability of tacrolimus is increased due to diminished activity of the CYP3A system and/or ABCB1 in damaged enterocytes [44]. Secondly, a higher amount of tacrolimus may be delivered to the colon due to a shortened ileal transit time. In the colon, a lower metabolic activity of CYP3A could result in increased absorption [45]. Therefore, it is recommended to monitor tacrolimus levels intensively during and shortly after an episode of diarrhea. Although CsA, mTOR inhibitors and CS are also substrates for CYP3A isoenzymes and ABCB1, increased exposure during diarrhea has not been described for these drugs. This suggests that the intestinal metabolism contributes lesser to total drug clearance for these drugs than in the case of tacrolimus [46]. There are no reports about the effect of diarrhea on AZA and mycophenolate exposure.

5. Gastrointestinal side effects of immunosuppressive drugs

Although GI adverse effects of immunosuppressive drugs are commonly reported, delineating the adverse effect profile of each individual drug is hampered by the fact that most patients use a combination of immunosuppressive agents. Moreover, it can be difficult to distinguish side effects from complaints due to the underlying renal disease. In the section below and in Table 2, we summarize the reported GI adverse effects of each agent separately.

5.1. Tacrolimus

A meta-analysis of randomized trials comparing tacrolimus to CsA revealed that GI adverse effects, especially diarrhea, are more common in patients treated with tacrolimus than in those treated with CsA [47]. A cross-sectional study with 543 renal transplant patients who all underwent upper endoscopy because of GI complaints, showed that renal allograft recipients receiving an immunosuppressive regimen consisting of tacrolimus, CS and MMF had a higher frequency of erosive lesions in the upper GI tract (24.4%) as compared to patients treated with CsA-CS-MMF (18.4%) or CsA-CS (15.9%) [48]. However, a difference in the incidence of upper GI complications between patients on tacrolimus and those on CsA is not a uniform finding [49]. Finally, case reports about tacrolimus-induced pancreatitis have been published, possibly related to higher tacrolimus blood levels [50,51].

5.2. Cyclosporine

Gingival hyperplasia is a well-known complication of the use of CsA and might be associated with *ABCB1* polymorphism since the transporter is expressed in the endothelial layers of blood vessels in gingival tissue [52]. Hyperplasia can be aggravated by concomitant use of calcium channel blockers and inflammatory processes due to dental plaque accumulation and other local factors [53]. Appropriate oral hygiene and cessation of the calcium channel blocker are the cornerstones for reducing the severity of gingival overgrowth. If hyperplasia persists, discontinuation of CsA and switch to another immunosuppressive agent should be pursued. Treatment with azithromycin may improve gingival hyperplasia, but increases CsA levels due to inhibition of its metabolism and is thus not routinely recommended [54].

Table 2
GI adverse effects of various immunosuppressive agents.

	Oral ulcers/stomatitis	Gingival hyperplasia	Nausea /vomiting/dyspepsia	Gastroparesis	Pancreatitis	Chronic diarrhea	Constipation
Tacrolimus	+	0	++	0/+	0/+	++	+
Cyclosporine	0	+	+	+	0/+	+	0
mTOR inhibitors	++	0	++	0	0/+	++	++
Corticosteroids	0	0	+	0	+	0	0
Azathioprine	0	0	+	0	+	0	0
Mycophenolate	+	0/+	++	0	0/+	++	+

Undesirable effects are listed using the following categories: ++ very common ($\geq 1/10$); + common ($\geq 1/100$ to $< 1/10$); 0/+ uncommon ($\geq 1/1000$ to $< 1/100$); 0 rare ($< 1/1000$).

CsA slows the gastric emptying of solid foods and therefore patients can suffer from dyspepsia and nausea although these complaints are less frequent than in tacrolimus treated patients (see above).

Moreover, CsA may be able to induce acute pancreatitis. The incidence reported in renal transplant patients treated with CsA is approximately 3% [55].

Diarrhea occurs in CsA treated patients, with a reported incidence between 14 and 47% [56]. The mechanism of CsA-induced diarrhea is unclear [56]. Constipation is also reported and appears to be more frequent in patients treated with CsA than in those treated with tacrolimus [47].

5.3. mTOR inhibitors

A bothersome GI complaint in patients receiving sirolimus is the occurrence of oral aphthous ulcers. It has been suggested that ulceration is caused by a direct toxic effect of sirolimus on the oral mucous membranes [57], but also the antiproliferative effect of sirolimus and the effect on growth factors could play a causal role [58]. The wide variability in the frequency of aphthous ulcers (10–100%) is probably related to various factors like the moment of introduction, the underlying circumstances, and the applied treatment protocols. For example, lack of CS co-administration may increase the incidence of oral ulcers [59]. Chronic fissure of the lips and chronic gingivitis were also reported to be common (20% and 11%, respectively) in patients treated with sirolimus [57]. Although reported less frequently, mouth ulceration has been described in patients treated with everolimus too [60].

The manufacturer reports that the incidence of diarrhea with sirolimus varies from 25% to 42% [61]. Suggested mechanisms are downregulation of the Na⁺/H⁺ exchanger 3 expression in apical membranes of the intestines and lipid malabsorption [62,63]. Furthermore, since sirolimus has, like tacrolimus, a macrolide chemical structure, prokinetic effects may contribute to the occurrence of diarrhea [64]. Other reported adverse effects of mTOR inhibitors include abdominal pain, nausea, vomiting, dyspepsia, and notably also constipation.

5.4. Mycophenolate

Patients using MMF frequently experience nausea, vomiting, heartburn, dyspepsia, anorexia, and especially diarrhea. In three clinical trials where MMF was combined with CsA in renal transplant recipients, the incidence of diarrhea within the first year after transplantation ranged from 15.6% to 32.5% for a 2000 mg daily dose of MMF [65–67]. In patients using the combination of tacrolimus and MMF, the reported incidence of diarrhea is even higher [68]. The mechanisms responsible for GI intolerance and especially diarrhea are still a matter of debate. The symptoms usually resolve after a dose reduction, a temporary interruption, or a complete discontinuation of MMF. The intravenous administration of MMF is associated with a higher incidence of GI adverse events as compared to oral administration and this suggests that systemic exposure to MPA and/or its metabolites contributes to GI adverse effects [69]. However, no relation was demonstrated between diarrhea and the plasma concentration of the reactive acylglucuronide metabolite of MPA [70].

In patients with MMF-associated diarrhea villous atrophy in the duodenum and erosive inflammation in the ileum have been observed [71,72]. It was suggested that local effects of acylglucuronides metabolites, that are excreted with bile in the intestine, might provoke diarrhea [70]. Patients who use CsA and carriers of a biliary transporter polymorphism which reduces the excretion of MPA metabolites, could therefore have less diarrhea [73]. Others suppose that MMF impairs the global enterocyte function through either a higher apoptotic rate or an impaired function of the tight junctions leading to leak-flux diarrhea [74]. Besides, some authors have reported severe oral and colonic ulcerations that were suggested to be attributable to MMF toxicity [75,76]. In some patients the use of MMF has been linked to a Crohn's-like enterocolitis, which responded to discontinuation of the drug [77]. The exact mechanism underlying these ulcerations is unknown, but a direct toxic injury of MPA on the GI mucosa may be involved.

The enteric coated formulation of MPA, EC-MPS, was developed with the perspective to reduce the incidence of GI adverse events. In open-label studies an improvement in GI tolerability after conversion from MMF to EC-MPS was indeed observed [78,79]. EC-MPS might therefore be a useful alternative in some patients who suffer from MMF-related GI symptoms. However, in comparative studies with MMF used in an equipotent dose, the overall incidence and the profile of GI adverse events were similar in patients treated with either MMF or EC-MPS [80,81].

5.5. Azathioprine

In a retrospective review on side effects of AZA, GI complaints were reported in 19 of the 542 patients [82]. Approximately 10% of the patients had nausea and/or vomiting while GI symptoms not otherwise specified were reported in 6% of the patients. There are only two cases described of chronic diarrhea with severe villous atrophy possibly induced by AZA [83,84]. Acute pancreatitis due to AZA is a dreaded complication and was predominantly described in patients with inflammatory bowel disease [85].

In rare cases, a syndrome mimicking serious gastroenteritis may occur after administration of AZA [86].

5.6. Corticosteroids

Adverse effects of CS on the GI system include peptic ulcers, upper GI bleeding, pancreatitis, diverticular perforation, and malakoplakia. A meta-analysis comparing CS therapy for any medical condition to placebo revealed that the use of CS increased the risk of GI bleeding or perforation by 40%, especially in hospitalized patients [87].

CS have been listed as a cause for drug-induced acute pancreatitis [88]. In contrast, experimental studies have shown survival benefit with the use of hydrocortisone in animal models of acute pancreatitis [89]. However, the potential of CS to prevent pancreatitis after endoscopic retrograde cholangiopancreatography could not be demonstrated in clinical trials [90].

Colonic malakoplakia, a chronic granulomatous disease, is linked to the use of CS but also to the use of other immunosuppressive drugs [91].

5.7. Belatacept

Belatacept is a costimulation blocking agent that has to be administered intravenously. In two phase III trials (BENEFIT and BENEFIT-EXT), the incidence of GI side effects, as constipation, diarrhea and nausea was comparable between belatacept and CsA treated patients [92,93]. Several case reports describe development of inflammatory bowel disease during belatacept treatment [94,95].

6. Interaction between drugs targeting the gastrointestinal tract and immunosuppressive drugs

Some commonly given GI targeting drugs can affect the exposure to immunosuppressive drugs. The potential interactions are presented in Table 3 and are described in the following sections.

6.1. Prokinetic agents

Prokinetic agents like metoclopramide can increase the bioavailability of CNIs, mTOR inhibitors and CS by accelerated gastric emptying while metabolic capacity is less in the distal intestine. This phenomenon has especially been described for the combination of metoclopramide and CNIs [96]. Moreover, domperidone and ondansetron are substrates for ABCB1 and are metabolized by CYP3A4. Interactions with CNIs, mTOR inhibitors and CS might thus occur, but they have not been reported.

6.2. Antacids

The concomitant use of antacids containing aluminum and magnesium hydroxides reduces the exposure to MPA as a consequence of diminished absorption [97]. It is most likely explained by chelation, although an increase of the gastric pH with decline of elution and hydrolysis of mycophenolate might be an alternative explanation.

6.3. Proton pump inhibitors

Combined treatment with MMF and proton pump inhibitors (PPIs) reduces the exposure to MPA due to a decreased de-esterification of MMF [98,99]. This could result in undesired under-immunosuppression. A higher rate of acute rejection in renal transplant patients receiving PPIs next to MMF was observed in African Americans, but not in other populations [100]. The pharmacokinetics of EC-MPS is not affected by PPI co-administration as metabolism does not depend on the gastric pH [101].

PPIs are metabolized by cytochrome P450 enzymes, most notably by CYP2C19 but also by CYP3A4. Reduced activity of the CYP2C19 enzyme leads to an increased reliance on CYP3A4 for PPI metabolism. In this situation, an interaction with tacrolimus, resulting in increased tacrolimus levels has been described. Since the extent of metabolism by CYP2C19 versus CYP3A4 differs for the various PPIs, the risk for this type of interaction also varies per PPI [102].

6.4. H2 antagonists

Although H2 antagonists suppress gastric acid secretion, their effect on gastric pH is less than that of PPIs and there is no impact on the exposure to MPA [99]. Of note, it should be taken into account that serum creatinine usually rises after starting with cimetidine due to inhibition of the tubular secretion of creatinine, without a change in the glomerular filtration rate.

6.5. *Helicobacter pylori* eradication regimens

Triple therapy based on a PPI combined with clarithromycin and amoxicillin and/or metronidazole is the established first-line therapy for *Helicobacter pylori* eradication [103]. An interaction of clarithromycin with CNI, mTOR inhibitors or CS can occur via inhibition of CYP3A and ABCB1. Therefore, an alternative eradication regimen should be considered in transplant patients using these drugs, although intensified therapeutic drug monitoring is also an option. A disadvantage of the alternative eradication regimen consisting of PPI, levofloxacin and amoxicillin is the rising rates of levofloxacin resistance [103]. Moreover, concomitant use of metronidazole reduced the exposure to MPA with approximately 19% in healthy subjects [104]. This interaction is caused by disruption of the enterohepatic recirculation of MPA [29].

6.6. Loperamide and laxatives

Loperamide and most laxatives do not have clinically relevant interactions with immunosuppressive drugs. In rats, it was established that CsA increased the brain concentration of loperamide by inhibiting ABCB1 in the blood brain barrier [105]. However, such an effect has never been described for the intestinal ABCB1. The only laxatives showing an interaction with immunosuppressive drugs are magnesium containing ones, which reduce the bioavailability of MPA.

7. Conclusion

Most immunosuppressive agents are metabolized to a substantial extent in the GI tract. GI disorders can therefore affect the exposure to these agents. Knowledge on the involvement of transport proteins and metabolizing enzymes will help to better understand the consequences of GI tract disease and disturbances on immunosuppressive therapy. On the other hand, immunosuppressive agents can have adverse effects on the GI tract that affect quality of life, and can even have impact on patient or allograft survival. For physicians who prescribe immunosuppressive drugs to organ transplant recipients it is important to realize this reciprocal interaction.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Table 3

Interactions between commonly used GI targeting drugs and immunosuppressive agents.

	Prokinetics	Antacids	Proton pump inhibitors	H2 antagonists	Hp eradication	Antidiarrheals	Laxatives
Tacrolimus	±	—	±	—	+	—	—
Cyclosporine	±	—	—	—	+	—	—
mTOR inhibitors	—	—	—	—	+	—	—
Corticosteroids	—	—	—	—	—	—	—
Azathioprine	—	—	—	—	—	—	—
Mycophenolate	—	+	±	—	+	—	±

Interactions are symbolized as follows: +: proven interaction; ±: possible interaction; —: interaction not reported.

Hp: *Helicobacter pylori*.

Declaration of interest

L.B. Hilbrands has received fees for memberships of Scientific Advisory Boards of Novartis and Chiesi.

T. van Gelder has received lecture fees from Roche, Chiesi and Astellas Pharma, in addition to consulting fees from Roche Diagnostics, Astellas and Novartis.

M.M. Tielemans, G.A.J. van Boekel and E.T.T.L. Tjwa do not have any conflicts of interest.

References

- [1] Ekberg H, Kyllonen L, Madsen S, Grave G, Solbu D, Holdaas H. Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients. *Transplantation* 2007;83:282–9.
- [2] Bunnapradist S, Neri L, Wong W, Lentine KL, Burroughs TE, Pinsky BW, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. *Am J Kidney Dis* 2008;51:478–86.
- [3] Denhaerynck K, Dobbels F, Cleemput I, Desmytere A, Schafer-Keller P, Schaub S, et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. *Transpl Int* 2005;18:1121–33.
- [4] Knops N, Levchenko E, van den Heuvel B, Kuypers D. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. *Int J Pharm* 2013;452:14–35.
- [5] Budde K, Bunnapradist S, Grinyo JM, Ciechanowski K, Denny JE, Silva HT, et al. Novel Once-Daily Extended-Release Tacrolimus (LCPT) Versus Twice-Daily Tacrolimus in De Novo Kidney Transplants: One-Year results of phase III, Double-blind, Randomized Trial. *Am J Transplant* 2014;14:2796–806.
- [6] Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. *Clin Pharmacokinet* 2010;49:141–75.
- [7] von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. *Clin Pharmacol Ther* 2004;75:172–83.
- [8] Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. *J Pharmacol Exp Ther* 1997;283:1552–62.
- [9] Canaparo R, Finnstrom N, Serpe L, Nordmark A, Muntoni E, Eandi M, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. *Clin Exp Pharmacol Physiol* 2007;34:1138–44.
- [10] Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. *Clin Pharmacokinet* 1998;34:429–55.
- [11] Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. *Am J Transplant* 2005;5:987–94.
- [12] van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. *Ther Drug Monit* 2001;23:119–28.
- [13] Colom H, Lloberas N, Andreu F, Caldes A, Torras J, Oppenheimer F, et al. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. *Kidney Int* 2014;85:1434–43.
- [14] van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. *J Am Soc Nephrol* 2006;17:871–80.
- [15] Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. *Scand J Gastroenterol Suppl* 1998;225:92–9.
- [16] Gervasio JM, Brown RO, Lima J, Tabbaa MG, Abell T, Werkman R, et al. Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. *Dig Dis Sci* 2000;45:1601–7.
- [17] Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. *Am J Transplant* 2012;12:3326–36.
- [18] Romano P, Agena F, de Almeida Rezende Ebner P, Massakazu Sumita N, Kamada Triboni AH, Ramos F, et al. Longitudinal pharmacokinetics of mycophenolic acid in elderly renal transplant recipients compared to a younger control group: Data from the nEverOld Trial. *Eur J Drug Metab Pharmacokinet* 2018. <https://doi.org/10.1007/s13318-018-0506-6> (in press), [Epub ahead of print].
- [19] Nakamura Y, Takeuchi H, Okuyama K, Akashi T, Jojima Y, Konno O, et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. *Transplant Proc* 2005;37:1725–7.
- [20] Ishizawa T, Sugawara Y, Ikeda M, Hasegawa K, Makuuchi M. Optimal initial dose of orally administered cyclosporine following intravenous cyclosporine therapy. *Transplant Proc* 2005;37:4370–2.
- [21] Pescovitz MD, Conti D, Dunn J, Gonwa T, Halloran P, Sollinger H, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. *Clin Transplant* 2000;14:179–88.
- [22] Stiff T, Vanmolkot F, Scheffers I, van Bortel L, Neef C, Christiaans M. Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers. *Br J Clin Pharmacol* 2014;78:996–1004.
- [23] Sandborn WJ, Strong RM, Forland SC, Chase RE, Cutler RE. The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration. *J Clin Pharmacol* 1991;31:76–80.
- [24] Newrick PG, Braatvedt G, Hancock J, Corral RJ. Self-management of adrenal insufficiency by rectal hydrocortisone. *Lancet* 1990;335:212–3.
- [25] Reding R, Sokal E, Paul K, Janssens M, Evrard V, Wilmotte L, et al. Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients. *Pediatr Transplant* 2002;6:124–6.
- [26] Solari S, Cancino A, Wolff R, Norero B, Vargas JI, Barrera F, et al. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. *Aliment Pharmacol Ther* 2017;45:1225–31.
- [27] Rasmussen A, Hjortrup A, Hansen B, Heslet L, Kirkegaard P. Induction of immunosuppression by microemulsion cyclosporine in liver transplantation. *Transplantation* 1996;62:1031–3.
- [28] Kelly PA, Napoli K, Kahan BD. Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. *Biopharm Drug Dispos* 1999;20:249–53.
- [29] Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. *Clin Pharmacokinet* 2007;46:13–58.
- [30] Gastroparesis Hasler WL. *Curr Opin Gastroenterol* 2012;28:621–8.
- [31] Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. *Lancet* 1991;338:1488–90.
- [32] Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients. *Drug Metab Dispos* 2004;32:1421–5.
- [33] Maes BD, Vanwalleghem J, Kuypers D, Ghooys Y, Rutgeerts PJ, Vanrenterghem YF. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. *Transplantation* 1999;68:1482–5.
- [34] Naesens M, Verbeke K, Vanrenterghem Y, Kuypers D. Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. *Br J Clin Pharmacol* 2007;63:541–7.
- [35] Maes BD, Evenepoel P, Kuypers D, Geypens B, Ghooys Y, Vanrenterghem Y. Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. *Clin Transplant* 2003;17:171–6.
- [36] Hasegawa T, Nara K, Kimura T, Soh H, Sasaki T, Azuma T, et al. Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. *Pediatr Transplant* 2001;5:204–9.
- [37] Thielke J, Martin J, Weber FL, Schroeder TJ, Goresky S, Hanto DW. Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome. *Liver Transpl Surg* 1998;4:432–4.
- [38] Chenhsu RY, Wu Y, Katz D, Rayhill S. Dose-adjusted cyclosporine c2 in a patient with jejunoileal bypass as compared to seven other liver transplant recipients. *Ther Drug Monit* 2003;25:665–70.
- [39] Goransson LG, Bergrem H. Disappearance of measurable mycophenolate mofetil (Cell Cept) in a patient with a renal transplant and an ileostomy. *Nephrol Dial Transplant* 2002;17:318–9.
- [40] Bergrem H, Opedal I. Bioavailability of prednisolone in patients with intestinal malabsorption: the importance of measuring serum protein-binding. *Scand J Gastroenterol* 1983;18:545–9.
- [41] Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. *Clin Transplant* 2008;22:281–91.
- [42] Brocks DR, Ben-Eltriki M, Gabr RQ, Padwal RS. The effects of gastric bypass surgery on drug absorption and pharmacokinetics. *Expert Opin Drug Metab Toxicol* 2012;8:1505–19.
- [43] Diwan TS, Lichvar AB, Leino AD, Vinks AA, Christians U, Shields AR, et al. Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. *Clin Transplant* 2017;31.
- [44] Nakamura A, Amada N, Haga I, Tokodai K, Kashiwadate T. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. *Transplant Proc* 2014;46:592–4.
- [45] Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. *Br J Clin Pharmacol* 2005;60:54–60.
- [46] Maes BD, Lemahieu W, Kuypers D, Evenepoel P, Coosemans W, Pirenne J, et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. *Am J Transplant* 2002;2:989–92.
- [47] Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. *BMJ* 2005;331:810.
- [48] Telkes G, Peter A, Tulassay Z, Asderakis A. High frequency of ulcers, not associated with *Helicobacter pylori*, in the stomach in the first year after kidney transplantation. *Nephrol Dial Transplant* 2011;26:727–32.
- [49] Logan AJ, Morris-Stiff GJ, Bowrey DJ, Jurewicz WA. Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study. *Clin Transplant* 2002;16:163–7.
- [50] Ogunsinde BA, Wimmers E, Washington B, Iyob M, Cropper T, Callender CO. A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant. *Transplantation* 2003;76:448.

- [51] Im MS, Ahn HS, Cho HJ, Kim KB, Lee HY. Diabetic ketoacidosis associated with acute pancreatitis in a heart transplant recipient treated with tacrolimus. *Exp Clin Transplant* 2013;11:72–4.
- [52] Garcia M, Macias RM, Cubero JJ, Benitez J, Caravaca F, Gervasini G. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. *Eur J Clin Pharmacol* 2013;69:385–93.
- [53] Sukkar TZ, Thomason JM, Cawston TE, Lakey R, Jones D, Catterall J, et al. Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflammatory cytokines. *J Periodontol Res* 2007;42:580–8.
- [54] Nash MM, Zaltzman JS. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. *Transplantation* 1998;65:1611–5.
- [55] Yoshimura N, Nakai I, Ohmori Y, Aikawa I, Fukuda M, Yasumura T, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. *Am J Kidney Dis* 1988;12:11–7.
- [56] Malinowski M, Martus P, Lock JF, Neuhaus P, Stockmann M. Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function. *Transpl Int* 2011;24:184–93.
- [57] Mahe E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. *Transplantation* 2005;79:476–82.
- [58] Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. *Transplantation* 1999;67:1036–42.
- [59] van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. *Transplantation* 2003;75:788–91.
- [60] Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, et al. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. *J Am Soc Nephrol* 2018;29:1979–91.
- [61] Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. *Am J Health Syst Pharm* 2000;57:437–48 [quiz 49–51].
- [62] Yang J, Zhao X, Patel A, Potru R, Azizi-Ghannad S, Dolinger M, et al. Rapamycin Inhibition of mTOR Reduces Levels of the Na⁺/H⁺ Exchanger 3 in Intestines of mice and Humans, Leading to Diarrhea. *Gastroenterology* 2015;149:151–62.
- [63] Dias VC, Madsen KL, Mulder KE, Keelan N, Yatscoff RW, Thomson AB. Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits. *Dig Dis Sci* 1998;43:2227–36.
- [64] Alkhatib AA. Sirolimus-induced intractable chronic diarrhea: a case report. *Transplant Proc* 2006;38:1298–300.
- [65] Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. *Lancet* 1995;345:1321–5.
- [66] Blinded A. Randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. *Transplantation* 1996;61:1029–37.
- [67] Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. *Transplantation* 1995;60:225–32.
- [68] Squifflet JP, Backman L, Claesson K, Dietl KH, Ekberg H, Forsythe JL, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. *Transplantation* 2001;72:63–9.
- [69] Meier-Kriesche HU, Davies NM, Grinyo J, Heading R, Mamelok R, Wijngaard P, et al. Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil. *Am J Transplant* 2005;5:1164 [author reply 5–6].
- [70] Heller T, van Gelder T, Budde K, de Fijter JW, Kuypers D, Arns W, et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. *Am J Transplant* 2007;7:1822–31.
- [71] Kamar N, Faure P, Dupuis E, Cointault O, Joseph-Hein K, Durand D, et al. Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. *Transpl Int* 2004;17:463–7.
- [72] Maes BD, Dalle I, Geboes K, Oellerich M, Armstrong VW, Evenepoel P, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. *Transplantation* 2003;75:665–72.
- [73] Woillard JB, Rerolle JP, Picard N, Rousseau A, Drouet M, Munteanu E, et al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. *Br J Clin Pharmacol* 2010;69:675–83.
- [74] Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. *Clin Pharmacol Ther* 2001;69:24–31.
- [75] Golconda MS, Valente JF, Bejarano P, Gilinsky N, First MR. Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients. *Transplant Proc* 1999;31:272–3.
- [76] Naranjo J, Poniachik J, Cisco D, Contreras J, Oksenberg D, Valera JM, et al. Oral ulcers produced by mycophenolate mofetil in two liver transplant patients. *Transplant Proc* 2007;39:612–4.
- [77] Dost D, van Leerdaam ME, van Dekken H, Weimar W, Kuipers EJ, Bijl AH, et al. Crohn's-like enterocolitis associated with mycophenolic acid treatment. *Gut* 2008;57:1330.
- [78] Ortega F, Sanchez-Fructuoso A, Cruzado JM, Gomez-Alamillo JC, Alarcon A, Pallardo L, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. *Transplantation* 2011;92:426–32.
- [79] Burg M, Saemann MD, Wieser C, Kramer S, Fischer W, Lhotka K. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients. *Transplant Proc* 2009;41:4159–64.
- [80] Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. *Am J Transplant* 2004;4:237–43.
- [81] Kamar N, Oufroukhi L, Faure P, Ribes D, Cointault O, Lavyssiere L, et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. *Nephrol Dial Transplant* 2005;20:2231–6.
- [82] Whisnant JK, Pelkey J. Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. *Ann Rheum Dis* 1982;41:44–7.
- [83] Ziegler TR, Fernandez-Estivariz C, Gu LH, Fried MW, Leader LM. Severe villus atrophy and chronic malabsorption induced by azathioprine. *Gastroenterology* 2003;124:1950–7.
- [84] Weclawski H, Ould-Mohamed A, Bournet B, Guilbeau-Frugier C, Fortenfant F, Muscarelli F, et al. Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation. *Am J Transplant* 2011;11:575–82.
- [85] Ledder O, Lemberg DA, Day AS. Thiopurine-induced pancreatitis in inflammatory bowel diseases. *Expert Rev Gastroenterol Hepatol* 2015;9:399–403.
- [86] Marbet U, Schmid I. Severe life-threatening diarrhea caused by azathioprine but not by 6-mercaptopurine. *Digestion* 2001;63:139–42.
- [87] Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. *BMJ Open* 2014;4:e004587.
- [88] Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J. Drug-induced pancreatitis. *Curr Gastroenterol Rep* 2012;14:131–8.
- [89] Pescador R, Manso MA, Rebollo AJ, de Dios I. Effect of chronic administration of hydrocortisone on the induction and evolution of acute pancreatitis induced by cerulein. *Pancreas* 1995;11:165–72.
- [90] Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. *Gastrointest Endosc* 2002;55:470–5.
- [91] Bae GE, Yoon N, Park HY, Ha SY, Cho J, Lee Y, et al. Silent Colonic Malakoplakia in a Living-Donor Kidney Transplant Recipient Diagnosed during Annual Medical Examination. *Korean J Pathol* 2013;47:163–6.
- [92] Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFT-EXT study). *Am J Transplant* 2010;10:547–57.
- [93] Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFT study). *Am J Transplant* 2010;10:535–46.
- [94] Motohashi R, Ikeuchi H, Hiromura K, Ohishi Y, Sakurai N, Sakairi T, et al. Two cases of ulcerative colitis developing in rheumatoid arthritis patients during abatacept therapy. *Scand J Gastroenterol* 2014;49:1270–1.
- [95] Bozon A, Jeantet G, Riviere B, Funakoshi N, Dufour G, Combes R, et al. Stricturing Crohn's disease-like colitis in a patient treated with belatacept. *World J Gastroenterol* 2017;23:8660–5.
- [96] Prescott Jr WA, Callahan BL, Park JM. Tacrolimus toxicity associated with concomitant metoclopramide therapy. *Pharmacotherapy* 2004;24:532–7.
- [97] Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. *Br J Clin Pharmacol* 1996;41:513–6.
- [98] Schaefer M, Scholl C, Scharpf D, Hug F, Bonisch-Schmidt S, Dikow R, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. *Rheumatology (Oxford)* 2010;49:2061–7.
- [99] Kofler S, Shvets N, Bigdeli AK, König MA, Kaczmarek P, Deutsch MA, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients—a prospective case-controlled study. *Am J Transplant* 2009;9:1650–6.
- [100] van Boekel GA, Kerkhofs CH, van de Logt F, Hilbrands LB. Proton pump inhibitors do not increase the risk of acute rejection. *Neth J Med* 2014;72:86–90.
- [101] Kees MG, Steinke T, Moritz S, Rupprecht K, Paulus EM, Kees F, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. *J Clin Pharmacol* 2012;52:1265–72.
- [102] Maguire M, Franz T, Hains DS. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. *Pediatr Transplant* 2011.
- [103] Selgrad M, Malfertheiner P. Treatment of *Helicobacter pylori*. *Curr Opin Gastroenterol* 2011;6:565–70.
- [104] Naderer OJ, Dupuis RE, Heinzen EL, Wiwattanawongsa K, Johnson MW, Smith PC. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. *J Clin Pharmacol* 2005;45:219–26.
- [105] Hsiao P, Unadkat JD. P-glycoprotein-based loperamide-cyclosporine drug interaction to the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans. *Mol Pharm* 2012;9:629–33.
- [106] Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. *Clin Pharmacokinet* 2001;40:283–95.
- [107] Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. *Clin Pharmacokinet* 1995;29:404–30.

- [108] Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. *J Clin Pharmacol* 2001;41:176–82.
- [109] Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. *Clin Pharmacokinet* 2014;53:123–39.
- [110] Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. *Transplantation* 2012;94:1013–9.
- [111] Metalidis C, Lerut E, Naesens M, Kuypers DR. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. *Transplantation* 2011;91:1098–102.
- [112] Cross SA, Perry CM. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients. *Drugs* 2007;67:1931–43.
- [113] Agency EM. Advagraf: summary of product characteristics. [online] [Available from <http://www.ema.europa.eu>.
- [114] Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. *Transplantation* 2013;96:191–7.
- [115] Agency EM. Envarsus: summary of product characteristics. [online] [Available from <http://www.ema.europa.eu>.
- [116] Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. *Clin Pharmacokinet* 2001;40:573–85.
- [117] Thervet E, Anglicheau D, Legendre C, Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. *Ther Drug Monit* 2008;30:143–50.
- [118] Zimmerman JJ, Ferron GM, Lim HK, Parker V. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). *J Clin Pharmacol* 1999;39:1155–61.
- [119] Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. *Am J Transplant* 2005;5:595–603.
- [120] Kirchner GL, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. *Clin Pharmacokinet* 2004;43:83–95.
- [121] Kovarik JM, Hartmann S, Figueiredo J, Rordorf C, Golor G, Lison A, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. *Pharmacotherapy* 2002;22:154–9.
- [122] Moes DJ, Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. *CPT Pharmacometrics Syst Pharmacol* 2014;3:e100.
- [123] Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kutz K. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients—a concentration-controlled comparison with the commercial formulation. *Transplantation* 1994;57:1178–82.
- [124] Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. *Drugs* 2001;61:1957–2016.
- [125] Bergmann TK, Barraclough KA, Lee KJ, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. *Clin Pharmacokinet* 2012;51:711–41.
- [126] Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. *Gut* 1996;39:63–8.